Information Provided By: 
Fly News Breaks for February 24, 2017
PTLA
Feb 24, 2017 | 05:56 EDT
Oppenheimer analyst Jay Olson upgraded Portola Pharmaceuticals to Outperform saying no FDA advisory panel is a ''clear positive" for betrixaban. The analyst is also "increasingly optimistic" about growth of the Factor Xa inhibitor class. He raised his price target for Portola shares to $40 from $28.
News For PTLA From the Last 2 Days
There are no results for your query PTLA
